eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
4/2023
vol. 25
 
Share:
Send email
Share:
Varia

Position of an expert panel on diagnosis of treatment of irritable bowel syndrome

Mateusz Babicki
1
,
Agnieszka Mastalerz-Migas
1
,
Magdalena Stolarczyk
2
,
Dorota Waśko-Czopnik
3
,
Adam Wichniak
4

  1. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
  2. District Pharmaceutical Chamber, Warsaw, Poland
  3. Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
  4. 3rd Division of Psychiatry and Sleep Disorders Centre at the Institute of Psychiatry and Neurology, Warsaw, Poland
Family Medicine & Primary Care Review 2023; 25(4): 472–479,
DOI: https://doi.org/10.5114/fmpcr.2023.132973
Online publish date: 2023/12/27
Article file
- 15 FM&PCR 4 23 - V - Babicki - 1435 - The position.pdf  [0.50 MB]
Get citation
 
PlumX metrics:
 
1. Stachowska E, Maciejewska D, Ryterska K, et al. Abdominal Pain and Disturbed Bowel Movements Are Frequent among Young People. A Population Based Study in Young Participants of the Woodstock Rock Festival in Poland. J Gastrointestin Liver Dis 2018; 27: 379–383, doi: 10.15403/JGLD.2014.1121.274.POL.
2. Canavan C, West J, Card, T. The Epidemiology of Irritable Bowel Syndrome. Clin Epidemiol 2014; 6: 71–80, doi: 10.2147/CLEP.S40245.
3. Adrych K. Zespół jelita drażliwego w świetle najnowszych wytycznych. Varia Medica 2019; 3: 89–95 (in Polish).
4. Rodińo-Janeiro BK, Vicario M, Alonso-Cotoner C, et al. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther 2018; 35: 289, doi: 10.1007/S12325-018-0673-5.
5. Oświęcimska J, Szymlak A, Roczniak W, et al. New Insights into the Pathogenesis and Treatment of Irritable Bowel Syn-drome. Adv Med Sci 2017; 62: 17–30, doi: 10.1016/J.ADVMS.2016.11.001.
6. Hadjivasilis A, Tsioutis C, Michalinos A, et al. New Insights into Irritable Bowel Syndrome: From Pathophysiology to Treatment. Ann Gastroenterol 2019; 32: 554, doi: 10.20524/AOG.2019.0428.
7. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil 2017; 23: 151–163, doi: 10.5056/JNM16214.
8. Hellström PM, Benno P. The Rome IV: Irritable Bowel Syndrome – A Functional Disorder. Best Pract Res Clin Gastroenterol 2019; 40–41, doi: 10.1016/J.BPG.2019.101634.
9. Pietrzak AP, Skrzydo-Radomaska B, Mulak A, et al. Guidelines on the Management of Irritable Bowel Syndrome. Gastroenterol Rev 2018; 13; 167–196, doi: 10.5114/pg.2018.78343.
10. Blake MR, Raker JM, Whelan K. Validity and Reliability of the Bristol Stool Form Scale in Healthy Adults and Patients with Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol Ther 2016; 44: 693–703, doi: 10.1111/APT.13746.
11. Irritable Bowel Syndrome (IBS) – Symptoms – NHS [cited 30.06.2023]. Available from URL: https://www.nhs.uk/conditions/irritable-bowel-syndrome-ibs/symptoms/.
12. Hadjivasilis A, Tsioutis C, Michalinos A, et al. New Insights into Irritable Bowel Syndrome: From Pathophysiology to Treatment. Ann Gastroenterol 2019; 32: 554–564, doi: 10.20524/AOG.2019.0428.
13. Masuy I, Pannemans J, Tack J. Irritable Bowel Syndrome: Diagnosis and Management. Minerva Gastroenterol Dietol 2020; 66: 136–150, doi: 10.23736/S1121-421X.19.02640-0.
14. Ford AC, Sperber AD, Corsetti M, et al. Lancet 2020; 396: 1675–1688, doi: 10.1016/S0140-6736(20)31548-8.
15. Black TP, Manolakis CS, Di Palma JA. “Red Flag” Evaluation Yield in Irritable Bowel Syndrome. J Gastrointestin Liver Dis 2012; 21(2): 153–156.
16. Bellini M, Tonarelli S, Nagy AG, et al. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients 2020; 12, doi: 10.3390/NU12010148.
17. Liu J, Chey WD, Haller E, et al. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Know and What We Have Yet to Learn. Annu Rev Med 2020; 71: 303–314, doi: 10.1146/ANNUREV-MED-050218-013625.
18. Savarino E, Zingone F, Barberio B, et al. Functional Bowel Disorders with Diarrhoea: Clinical Guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United Eur Gastroenterol J 2022; 10: 556–584, doi: 10.1002/UEG2.12259.
19. Hetterich L, Stengel A. Psychotherapeutic Interventions in Irritable Bowel Syndrome. Front Psychiatry 2020; 11, doi: 10.3389/FPSYT.2020.00286.
20. Dalrymple J, Bullock I. Diagnosis and Management of Irritable Bowel Syndrome in Adults in Primary Care: Summary of NICE Guidance. BMJ 2008; 336: 556–558, doi: 10.1136/BMJ.39484.712616.AD.
21. Moss-Morris R, McAlpine L, Didsbury LP, et al. A Randomized Controlled Trial of a Cognitive Behavioural Therapy-Based Self-Management Intervention for Irritable Bowel Syndrome in Primary Care. Psychol Med 2010; 40: 85–94, doi: 10.1017/S0033291709990195.
22. Kinsinger SW. Cognitive-Behavioral Therapy for Patients with Irritable Bowel Syndrome: Current Insights. Psychol Res Behav Manag 2017; 10: 231–237, doi: 10.2147/PRBM.S120817.
23. McCrone P, Knapp M, Kennedy T, et al. Cost-Effectiveness of Cognitive Behaviour Therapy in Addition to Mebeverine for Irritable Bowel Syndrome. Eur J Gastroenterol Hepatol 2008; 20: 255–263, doi: 10.1097/MEG.0B013E3282F2519D.
24. Alammar N, Wang L, Saberi B, et al. The Impact of Peppermint Oil on the Irritable Bowel Syndrome: A Meta-Analysis of the Pooled Clinical Data. BMC Complement Altern Med 2019; 19, doi: 10.1186/S12906-018-2409-0.
25. Li X, Li B, Zhang J, et al. Efficacy of Opioid Receptor Modulators in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2021; 100, doi: 10.1097/MD.0000000000024361.
26. Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 2021; 325: 865–877, doi: 10.1001/JAMA.2020. 22532.
27. Mebeweryna – Charakterystyka Produktu Leczniczego; 2023 (in Polish).
28. Alveryna – Charakterystyka Produktu Leczniczego; 2014: 1–4 (in Polish).
29. Drotaweryna – Charakterystyka Produktu Leczniczego; 2023 (in Polish).
30. Trimebutyna – Charakterystyka Produktu Leczniczego; 2017: 1–32 (in Polish).
31. Xue XC, Qi XX, Wan XY. Randomized Controlled Study of Efficacy and Safety of Drotaverine Hydrochloride in Patients with Irritable Bowel Syndrome. Medicine (Baltimore) 2017; 96, doi: 10.1097/MD.0000000000009235.
32. Rai R, Nijhawan S. Comparative Evaluation of Efficacy and Safety of Drotaverine versus Mebeverine in Irritable Bowel Syndrome: A Randomized Double-Blind Controlled Study. Saudi J Gastroenterol 2021; 27: 136–143, doi: 10.4103/SJG.SJG_266_20.
33. Darvish-Damavandi M, Nikfar S, Abdollahi M. A Systematic Review of Efficacy and Tolerability of Mebeverine in Irri-table Bowel Syndrome. World J Gastroenterol 2010; 16: 547–553, doi: 10.3748/WJG.V16.I5.547.
34. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, et al. The Efficacy of Mebeverine in the Treatment of Irrita-ble Bowel Syndrome – A Systematic Review. J Clin Med 2022; 11: 1044, doi: 10.3390/JCM11041044/S1.
35. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of Antispasmodic Agents, Alone or in Combination, in the Treatment of Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. Rev Gastroente-rol Mex 2012; 77: 82–90, doi: 10.1016/J.RGMX.2012.04.002.
36. Salvioli B. Trimebutine: A State-of-the-Art Review. Minerva Gastroenterol Dietol 2019; 65: 229–238, doi: 10.23736/S1121-421X.19.02567-4.
37. Chey WD, Shah ED, DuPont HL. Mechanism of Action and Therapeutic Benefit of Rifaximin in Patients with Irritable Bowel Syndrome: A Narrative Review. Therap Adv Gastroenterol 2020; 13, doi: 10.1177/1756284819897531.
38. Lewis PO, Khan I, Patel P. Rifampin-Resistant Staphylococcus Aureus Bacteremia in a Patient on Chronic Rifaximin. Ann Pharmacother 2017; 51: 617–618, doi: 10.1177/1060028017701221.
39. Valentin T, Leitner E, Rohn A, et al. Rifaximin Intake Leads to Emergence of Rifampin-Resistant Staphylococci. J Infect 2011; 62: 34–38, doi: 10.1016/J.JINF.2010.11.004.
40. Reigadas E, Muńoz-Pacheco P, Vázquez-Cuesta S, et al. Rifaximin-Resistant Clostridium Difficile Strains Isolated from Symptomatic Patients. Anaerobe 2017; 48: 269–272, doi: 10.1016/J.ANAEROBE.2017.10.002.
41. Kujanpää T, Ylisaukko-Oja T, Jokelainen J, et al. Prevalence of Anxiety Disorders among Finnish Primary Care High Utilizers and Validation of Finnish Translation of GAD-7 and GAD-2 Screening Tools. Scand J Prim Health Care 2014; 32: 78, doi: 10.3109/02813432.2014.920597.
42. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: Validity of a Two-Item Depression Screener. Med Care 2003; 41: 1284–1292, doi: 10.1097/01.MLR.0000093487.78664.3C.
43. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic Review with Meta-Analysis: The Prevalence of Anxiety and De-pression in Patients with Irritable Bowel Syndrome. Aliment Pharmacol Ther 2019; 50: 132–143, doi: 10.1111/APT.15325.
44. Oliva V, Lippi M, Paci R, et al. Gastrointestinal Side Effects Associated with Antidepressant Treatments in Patients with Major Depressive Disorder: A Systematic Review and Meta-Analysis. Prog Neuropsychopharmacol Biol Psychiatry 2021; 109, doi: 10.1016/J.PNPBP.2021.110266.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.